Cancer Vaccines

As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence an of improved understanding of autoimmune disease mechanisms and the availability of recombinant cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise of future improvements in outcomes for autoimmune disease patients. This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact on treatment options and the competitive landscape.

Publication: July 2008

Summary of Contents (see Prospectus for Full Contents)

Executive Summary

Market Overview

Oncology Market Dynamics

Shifting Therapeutic Approaches

The Demographics of Cancer

Factors Limiting Growth

Competitive Landscape

Therapeutic Vaccine Technology

Tumor Immunogenicity Factors

Cancer Antigen Selection

Vaccine Immunotherapy Design

Delivery/Vector Selection

Co-stimulators/Adjuvants

Vaccine Therapy Protocols

Vaccine Technology Factors

Unique vs. Shared Antigens

Single vs Polyvalent

Antigen/Epitope Source

Tissue Extracts

Immortalized Cell Lines

Synthesized Epitopes

Adjuvants

Carriers

Commercialization Factors

Vaccine Processing

Standardization and Personalized Medicine

Branded Therapeutic Vaccine Platforms

Tumor-derived

Targeted Antigen

Whole Tumor/Multivalent

Modified Dendritic Cells

Established Biomarkers

Modified Viral Vectors

DNA Vaccines

Fusion Proteins

Development-stage Vaccine Assessments

Therapeutic Vaccine Segment Analysis &

Commercial Assessment

Brain Cancer

Breast Cancer

Colon Cancer

Melanoma

Leukemias

Lymphomas

NSCLC

Pancreatic Cancers

Prostate Cancers

Renal Cancers

Reproductive Cancers

Commercialization Factors

Evolving Regulatory Climate

Clinical Trial Issues

Trial Endpoints

Non-platform Dependent Outcome

Variability

Managed Care Factors

Business Strategy Factors

Funding/Capitalization

Alliances & Partnerships

Intellectual Property/Patent Issues

Company Profiles

About Our Reports

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.